We are aware of the intended repurposing licence for Anastrazole in the prevention of breast cancer in women at moderate to high risk.
Unfortunately, it has been incorrectly broadcast that patients should seek information from their GP. We are awaiting further information regarding the correct pathway for patients to receive the appropriate assessment and treatment.
We apologise for any inconvenience this may have caused.
